A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer

A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer

Abstract Introduction Currently, only a few options are available for the treatment of patients with small‐cell lung cancer (SCLC) after the failure of first‐line platinum‐based chemotherapy. The present study aimed to evaluate the efficacy and safety of apatinib plus chemotherapy for second‐line tr...

Full description

Saved in:
Bibliographic Details
Main Authors: Yinghui Xu, Xu Wang, Chao Sun, Zhiru Gao, Hua He, Shi Qiu, Ye Guo, Xiaohui Ma, Junya Song, Kewei Ma
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Cancer Medicine
Subjects:
angiogenesis
apatinib
small cell lung cancer (SCLC)
targeted therapy
VEGFR2
Online Access:https://doi.org/10.1002/cam4.5217
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.5217

Similar Items